Nov 7, 2024 • 7:30 AM EST XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Oct 22, 2024 • 8:00 AM EDT XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
Sep 23, 2024 • 6:30 AM EDT Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
